Urothelial carcinoma is one of the most common malignancies worldwide. For patients with metastatic urothelial carcinoma (mUC), systemic chemotherapy has been the standard of care for many years but the development of new therapeutics is starting to expand treatment options. Here, you are invited to participate in this three-part case study series, which looks at how to manage patients with mUC.
Each case study will take up to 15 minutes to complete. Review the evidence, test your knowledge through these case-based self-assessments and help guide your everyday clinical practice.
Professor Aristotle Bamias presents an interactive case study on selecting the most adequate first-line treatment option for a cisplatin-ineligible patient.
Professor Jens Bedke presents an interactive case study on selecting the most adequate first-line treatment option for cisplatin-eligible patients and explains the standard maintenance therapy.
Professor Cora Sternberg presents an interactive case study which follows patients whose disease has progressed after first- and/or second-line therapy and considers available treatment options for these situations.
After completing this case study, you will be able to:
After completing this case study, you will be able to:
After completing this case study, you will be able to:
This independent programme is supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany
All content has been developed independently by Springer Healthcare IME, in conjunction with an expert Faculty.